The NMDA receptor is a key receptor for glutamate, the brain's primary excitatory neurotransmitter, and it plays a central role in regulating synaptic plasticity, learning/memory, cognition and mood.
Gate's lead programs are NMDAR positive allosteric modulators (PAMs) that bind to a unique site on the receptor to directly enhance glutamate signaling and improve synaptic function. Our mechanism is highly differentiated from other NMDAR-targeted therapies by avoiding the severe side effects of antagonists (i.e. ketamine) and overstimulation by other PAMs.
Directly enhancing synaptic function with our novel NMDAR PAMs represents a safer approach to achieve rapid and long-lasting treatment outcomes.
Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Once-Weekly Oral Zelquistinel In adults with Major Depressive Disorder
Randomized, Double-Blind, Placebo-Controlled Phase 2 study of Single-Dose IV Apimostinel in Combination with ASAT Digital Training in Adults with Major Depressive Disorder